Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + bevacizumab + gemcitabine
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the PD-1 inhibitor sintilimab, the anti-angiogenic agent bevacizumab, and the cytotoxic chemotherapy gemcitabine. It is being evaluated by Zhejiang Cancer Hospital as an induction regimen for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) who are ineligible for cisplatin-based therapy. Sintilimab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, thereby restoring T-cell mediated anti-tumor immunity. Bevacizumab is a recombinant humanized monoclonal antibody that binds to VEGF-A, preventing its interaction with receptors and inhibiting tumor angiogenesis. Gemcitabine is a nucleoside metabolic inhibitor that, once phosphorylated, inhibits ribonucleotide reductase and incorporates into DNA, leading to chain termination and apoptosis. The regimen is designed to provide a non-platinum-based alternative for induction therapy in NPC.
- Other names
- Sintilimab, bevacizumab, gemcitabine
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNA polymerase familyRNR (Ribonucleotide reductase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on sintilimab + bevacizumab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + bevacizumab + gemcitabine.